| Nov. 20, 2009 |
|
Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA® |
| Nov. 17, 2009 |
|
Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific Sessions |
| Nov. 17, 2009 |
|
Higher Dose of Merck's COZAAR® (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study |
| Nov. 15, 2009 |
|
Merck Expresses Confidence in the Efficacy and Safety Profiles of ZETIA® (ezetimibe) and VYTORIN® (ezetimibe/simvastatin) as Effective Medicines for Managing Elevated Cholesterol |
| Nov. 14, 2009 |
|
Merck Strengthens Its Commitment to Advancing Cardiovascular Health Care |
| Nov. 13, 2009 |
|
NYT Letter to the Editor from Dr. Richard Pasternak |
| Nov. 13, 2009 |
|
Merck Announces Completion of Patient Enrollment in Phase III TRA-2°P-TIMI 50 Trial of SCH 530348, a Novel, Oral Antiplatelet PAR-1 Inhibitor |
| Nov. 04, 2009 |
|
New Merck Begins Operations |
| Nov. 03, 2009 |
|
Merck and Schering-Plough to Complete Merger Today |
| Oct. 29, 2009 |
|
Merck and Schering-Plough Receive Approvals From U.S. Federal Trade Commission, Swiss Competition Commission and Canadian Competition Bureau for Merger |
| Oct. 23, 2009 |
|
Merck and Schering-Plough Receive Approval From European Commission for Merger |
| Oct. 22, 2009 |
|
The Supreme Court of Canada Will Not Review the Saskatchewan Court of Appeal Judgment Overturning a Class Certification Order in VIOXX® Action
|
| Oct. 22, 2009 |
|
Merck Announces Third-Quarter 2009 Financial Results |
| Oct. 21, 2009 |
|
CDC Advisory Committee on Immunization Practices Votes for Permissive Use and for Vaccines for Children Funding for GARDASIL® for Boys and Young Men |
| Oct. 19, 2009 |
|
Pediatricians Put Proven Treatment
Strategies to Work in Battle Against Asthma, Top Chronic
Disease For Children |
| Oct. 16, 2009 |
|
FDA Approves GARDASIL® for Use in Boys and Young Men |
| Oct. 08, 2009 |
|
300 Doctors at your Fingertips: New Merck Manuals Deliver Convenient and Trusted Medical Information to Consumers |
| Sep. 30, 2009 |
|
Merck & Co., Inc. Publishes 2008 Global Corporate Responsibility Report |
| Sep. 28, 2009 |
|
Merck & Co., Inc. Obtains Exclusive U.S. Marketing Rights for AFLURIA®, Seasonal Influenza Vaccine from CSL Biotherapies |
| Sep. 25, 2009 |
|
Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin) |
| Sep. 25, 2009 |
|
Merck Receives Positive CHMP Opinion for JANUVIA® (sitagliptin) and JANUMET® (sitagliptin/metformin) as Add-On to Insulin in the European Union |
| Sep. 24, 2009 |
|
Merck Statement on HIV Vaccine Trial |
| Sep. 23, 2009 |
|
Merck and QIAGEN Collaborate to Accelerate Access to Cervical Cancer Vaccination and Screening in Developing Countries |
| Sep. 18, 2009 |
|
Sanofi-aventis Completes Acquisition of Merck's Interest in Merial |
| Sep. 17, 2009 |
|
Wellcome Trust and Merck Launch First of Its Kind Joint Venture to Develop Affordable Vaccines for Low-Income Countries |
| Sep. 14, 2009 |
|
New, Long-Term Data for Odanacatib, Merck's Investigational Cat K Inhibitor, Showed Positive Results in Treating Osteoporosis |
| Sep. 13, 2009 |
|
Merck's ISENTRESS® (raltegravir) Tablets Studied in Comparison to Efavirenz in Combination Therapy Through 96 Weeks in HIV-1 Treatment-Naïve Patients |
| Sep. 11, 2009 |
|
Mistrial Declared in First Federal FOSAMAX® Trial |
| Sep. 10, 2009 |
|
Merck Updates Status of Clinical Development Programs for Investigational CGRP Receptor Antagonist Treatments for Acute Migraine; MK-3207 Clinical Development Discontinued |
| Sep. 09, 2009 |
|
FDA Advisory Committee Recommends Approval for Use of GARDASIL® in Boys and Men |
| Sep. 08, 2009 |
|
Merck & Co., Inc. Named to Dow Jones Sustainability North America Index |
| Sep. 03, 2009 |
|
Merck Launches SAFLUTAN® (tafluprost) in International Markets |
| Sep. 03, 2009 |
|
Three Directors Set For Newly-Combined Merck |
| Aug. 31, 2009 |
|
Merck CEO Announces Structure and Global Leadership Team for New Merck |
| Aug. 24, 2009 |
|
Merck to Hold Third-Quarter 2009 Sales and Earnings Conference Call on Oct. 22 |
| Aug. 20, 2009 |
|
Merck is Pleased the FDA and CDC Re-affirm the Safety Profile of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] |
| Aug 19, 2009 |
|
Merck Wins SINGULAIR® Patent Infringement Lawsuit |
| Aug. 18, 2009 |
|
New Study Reinforces Safety Profile of GARDASIL®, the Cervical Cancer Vaccine |
| Aug. 11, 2009 |
|
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court |
| Aug. 07, 2009 |
|
Merck Shareholders Approve Merger With Schering-Plough |
| Aug. 05, 2009 |
|
Merck and Schering-Plough Resolve Previously Disclosed Civil Class Action Lawsuits Related to VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe) |
| Jul. 31, 2009 |
|
FDA Approves Expanded Use of ISENTRESS® (raltegravir) in Combination Therapy for Adult Patients with HIV-1 Infection to Include Patients Not Previously Treated with HIV Medicines |
| Jul. 30, 2009 |
|
Sanofi-aventis to Acquire Merck's Interest in Merial |
| Jul. 29, 2009 |
|
Statement by Merck & Co., Inc., Regarding FOSAMAX® (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw |
| Jul. 28, 2009 |
|
Merck Announces Fourth-Quarter 2009 Dividend |
| Jul. 24, 2009 |
|
Merck Reports Proposed Settlement of Litigation Involving Planned Merger with Schering-Plough |
| Jul. 21, 2009 |
|
Merck Announces Second-Quarter 2009 Financial Results |
| Jul. 20, 2009 |
|
ISENTRESS® (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy |
| Jul. 20, 2009 |
|
Merck Issues Statement on WHO Study Showing First Evidence that Elimination of River Blindness Is Feasible in Africa |
| Jul. 15, 2009 |
|
Merck and Schering-Plough Resolve Previously Disclosed Investigation Under State Consumer Protection Statutes Related to VYTORIN® (ezetimibe/simvastatin) and ZETIA®(ezetimibe) |
| Jul. 09, 2009 |
|
Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, a Novel Investigational Oral Anticoagulant for Cardiovascular Disease |
| Jun. 29, 2009 |
|
Nation's Top 37 Minority Students Awarded Prestigious UNCF/MERCK Science Scholarships & Fellowships |
| Jun. 22, 2009 |
|
The Earth Institute and Merck & Co., Inc./The Merck Company Foundation partner to strengthen health services in rural Africa |
| Jun. 22, 2009 |
|
Merck and Schering-Plough Receive Request for Additional Information from FTC Regarding Proposed Merger |
| Jun. 22, 2009 |
|
Merck Prices $4.25 Billion Debt Offering |
| Jun. 22, 2009 |
|
Merck & Co., Inc. and Drugs for Neglected Diseases initiative Collaborate to Find Treatments for World's Most Neglected Tropical Diseases |
| Jun. 20, 2009 |
|
Merck & Co., Inc. Statement on Medicare Part D Assistance |
| Jun 12, 2009 |
|
Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR® (montelukast sodium) |
| Jun. 09, 2009 |
|
Corporations Need to Tackle Global Corruption as Strategic CSR Effort |
| Jun 08, 2009 |
|
Initial Therapy with JANUMET™ (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes |
| Jun. 06, 2009 |
|
In Investigational Studies, New Uses of JANUVIATM (sitagliptin) in Combination with Other Diabetes Medicines Resulted In Significant Blood Sugar-Lowering Efficacy for Patients with Type 2 Diabetes |
| Jun. 05, 2009 |
|
Rolofylline Did Not Demonstrate Efficacy for Acute Heart Failure in Clinical Trial |
| Jun. 02, 2009 |
|
Merck to Hold Second-Quarter 2009 Sales and Earnings Conference Call on July 21 |
| Jun. 01, 2009 |
|
AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen |
| May 29, 2009 |
|
Merck Statement on United States Patent & Trademark Office Decision to Reexamine the SINGULAIR® Patent |
| May 27, 2009 |
|
Schering-Plough and Merck Provide Update on Distribution Agreement |
| May 27, 2009 |
|
Merck Announces Third-Quarter 2009 Dividend |
| May 26, 2009 |
|
GARDASIL® is First Cervical Cancer Vaccine to Receive WHO Pre-qualification |
| May 19, 2009 |
|
Merck to Launch TREDAPTIVE™ (ER niacin/laropiprant) in International Markets Later This Year |
| May 13, 2009 |
|
Merck Statement on Missouri Court of Appeals Decision Affirming a Ruling Certifying a Class of Missouri Plaintiffs Seeking Out-of-Pocket VIOXX® Costs |
| May 11, 2009 |
|
Ontario Court Grants Merck Time to Appeal Class Certification of Vioxx Action |
| May 11, 2009 |
|
Merck & Co., Inc. Statement on Health Reform Meeting with President Obama |
| May 08, 2009 |
|
Studies of GARDASIL®, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference |
| May 08, 2009 |
|
Merck Statement on California Court Ruling Denying Certification of Class of Plaintiffs Seeking Reimbursement for VIOXX® Costs |
| Apr. 21, 2009 |
|
Merck Announces First-Quarter 2009 Financial Results |
| Apr. 15, 2009 |
|
Solar Energy Tapped to Power World Headquarters of Merck & Co., Inc. |
| Mar. 30, 2009 |
|
Court of Appeal for Saskatchewan Allows Merck's Appeal and Overturns Class Certification of Vioxx Action |
| Mar. 23, 2009 |
|
Merck Provides Update on Merger Financing |
| Mar. 23, 2009 |
|
Merck & Co., Inc. Provides Update on Previously-Disclosed U.S. Department of Justice Investigation Relating to VIOXX® |
| Mar. 18, 2009 |
|
Merck & Co., Inc. Donates Antimalarial Candidate to Medicines for Malaria Venture for Use in Developing World |
| Mar. 17, 2009 |
|
Merck Statement on New Jersey Court Ruling Denying Certification of Class of Plaintiffs Seeking Reimbursement for Out-of-Pocket VIOXX® Costs |
| Mar. 17, 2009 |
|
Merck Recognized for Environmental Leadership by US EPA With 2009 Energy Star® Sustained Excellence Award |
| Mar. 12, 2009 |
|
Merck Expands Its Patient Assistance Program To Allow More People To Receive Its Medicines For Free |
| Mar. 09, 2009 |
|
MERCK AND SCHERING-PLOUGH TO MERGE |
| Mar. 05, 2009 |
|
Merck & Co., Inc. Signs on to United Nations Global Compact |
| Feb. 25, 2009 |
|
Dr. Thomas Cech Nominated to Join Merck Board of Directors |
| Feb. 25, 2009 |
|
The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps |
| Feb. 24, 2009 |
|
Merck Announces Second-Quarter 2009 Dividend |
| Feb. 24, 2009 |
|
Merck to Hold First-Quarter 2009 Sales and Earnings Conference Call on April 21 |
| Feb. 17, 2009 |
|
Carlos E. Represas Elected to Merck Board of Directors |
| Feb. 12, 2009 |
|
Merck & Co., Inc. Acquires Biologic Manufacturing Capabilities and Developmental Follow-on Biologics Portfolio from Insmed |
| Feb. 03, 2009 |
|
Merck Announces Fourth-Quarter and Full-Year 2008 Financial Results |
| Feb. 02, 2009 |
|
Dr. D. Gary Gilliland, Internationally-Recognized Physician and Researcher, Joins Merck Research Labs as Head of Oncology Research |
| Jan. 05, 2009 |
|
Merck to Hold Fourth-Quarter 2008 Sales and Earnings Conference Call on Feb. 3 |
| Dec. 18, 2008 |
|
Merck & Co., Inc. Awards More Than $8 Million to Non-Profit Organizations in 2008 to Help Address HIV and AIDS Worldwide |
| Dec. 09, 2008 |
|
Merck Outlines Long-Term Prospects and Progress on Strategic Plan at 2008 Annual Business Briefing |
| Dec. 04, 2008 |
|
Merck Provides 2009 Financial Guidance; Reaffirms Guidance for 2008 and 2010 |
| Nov. 25, 2008 |
|
Merck Announces First Quarter 2009 Dividend |
| Nov. 24, 2008 |
|
Merck to Hold Guidance Conference Call and Web Cast on Dec. 4 |
| Nov. 17, 2008 |
|
Merck Announces Voluntary Delisting from Philadelphia Stock Exchange |
| Nov. 12, 2008 |
|
Public Health Officials Announce Progress in Elimination of Transmission Of the Tropical Disease River Blindness |
| Nov. 08, 2008 |
|
Merck Reaffirms Cardiovascular Research Commitment |
| Oct. 27, 2008 |
|
Merck & Co., Inc., Announces New Disclosures in Just-Released Corporate Responsibility Report |
| Oct. 22, 2008 |
|
Merck Reports Third-Quarter 2008 Financial Results |
| Oct. 02, 2008 |
|
Merck & Co., Inc. Awards Five Grants to Humanitarian Aid Partners |
| Sep. 26, 2008 |
|
Merck to Hold Third-Quarter 2008 Sales and Earnings Conference Call on Oct. 22 |
| Sep. 25, 2008 |
|
Merck Takes Important Steps to Enhance Transparency |
| Sep. 25, 2008 |
|
ISENTRESS™ (raltegravir) Awarded Prix Galien USA Top Honor |
| Sep. 18, 2008 |
|
The Merck Manual of Patient Symptoms Empowers a New Generation Of Health Care Professionals |
| Sep. 12, 2008 |
|
Star-Ledger Letter to the Editor from Dick Pasternak |
| Sep. 09, 2008 |
|
Federal Court of Appeals in a Divided Decision Reverses District Court Ruling Dismissing VIOXX® Securities Class Action |
| Sep. 05, 2008 |
|
NYT Letter to the Editor from Peter Kim |
| Aug. 20, 2008 |
|
NYT Letter to the Editor from Dick Clark |
| Aug. 18, 2008 |
|
The Merck Index Women in Chemistry Scholarships to be Presented at American Chemical Society National Meeting |
| Aug. 04, 2008 |
|
Merck Institute for Science Education Launches Three-Year Program to Improve Science Teaching in New Jersey and Pennsylvania Public Schools |
| Jul. 22, 2008 |
|
Merck Announces Fourth Quarter 2008 Dividend |
| Jul. 21, 2008 |
|
Merck Will Hold Second-Quarter 2008 Sales and Earnings Conference Call and Webcast at 5:30 PM (EDT) on July 21 |
| Jul. 21, 2008 |
|
Merck Reports Second-Quarter 2008 Financial Results |
| Jul. 17, 2008 |
|
Merck to Fund U.S. VIOXX® Product Liability Resolution Program |
| Jul. 15, 2008 |
|
Leslie A. "Les" Brun Elected to Merck Board of Directors |
| Jul. 11, 2008 |
|
TREDAPTIVE™ (nicotinic acid /laropiprant) Approved in the European Union: New Lipid-Modifying Therapy to Treat LDL-C, HDL-C and Triglycerides |
| Jun. 24, 2008 |
|
38 Students Receive Prestigious UNCF/Merck Science Initiative Award |
| Jun. 23, 2008 |
|
Merck to Hold Second-Quarter 2008 Sales and Earnings Conference Call and Webcast on July 21 |
| Jun. 04, 2008 |
|
New Jersey Supreme Court Dismisses Medical Monitoring Suit Filed by VIOXX® Plaintiffs |
| Jun. 03, 2008 |
|
The Merck Company Foundation Creates Alliance to Reduce Health Care Disparities in Diabetes |
| May 29, 2008 |
|
Merck Wins Appeal of First VIOXX® Case to go to Trial |
| May 27, 2008 |
|
Merck Announces Third-Quarter 2008 Dividend |
| May 22, 2008 |
|
Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced |
| May 20, 2008 |
|
National Society Of Black Engineers Honors UNCF/Merck Science Initiative With Golden Torch Award |
| May 20, 2008 |
|
Merck Resolves Investigations Under State Consumer Protection Statutes Related to VIOXX |
| May 14, 2008 |
|
Merck Wins Appeal in VIOXX® Case |
| May 05, 2008 |
|
Merck to Reduce U.S. Sales Force by 1,200 Positions |
| May 01, 2008 |
|
Merck Extends Enrollment Deadline in Program to Resolve U.S. VIOXX® Product Liability Lawsuits |
| Apr. 21, 2008 |
|
Merck Reports First-Quarter 2008 Financial Results |
| Apr. 15, 2008 |
|
Merck Responds to Journal of the American Medical Association Articles |
| Apr. 01, 2008 |
|
Deforming disease could be eliminated by 2015 |
| Mar. 20, 2008 |
|
Merck to Hold First-Quarter 2008 Sales and Earnings Conference Call and Webcast on April 21 |
| Mar. 03, 2008 |
|
Merck Progress Report on Enrollment in Program to Resolve U.S. VIOXX® Product Liability Lawsuits |
| Feb. 28, 2008 |
|
Merck Retains Interest in AstraZeneca LP Products |
| Feb. 26, 2008 |
|
Merck Announces Second-Quarter 2008 Dividend |
| Feb. 20, 2008 |
|
Merck Sets Target to Reduce Global Greenhouse Gas Emissions by 12 Percent |
| Feb. 07, 2008 |
|
Merck Resolves Federal and State Investigations Related to Certain Past Pricing And Certain Past Sales and Marketing Activities |
| Jan. 30, 2008 |
|
Merck Announces 2007 Financial Results Reflecting Revenue Growth from Key Products |
| Jan. 01, 2008 |
|
Merck to Hold Fourth-Quarter 2007 Sales and Earnings Conference Call and Webcast on Jan. 30 |
| Dec. 17, 2007 |
|
Harry Jacobson, M.D., Elected to Merck Board of Directors |
| Dec. 11, 2007 |
|
Merck Reviews Progress on Strategic Plan at 2007 Annual Business Briefing |
| Dec. 05, 2007 |
|
World Bank and Merck & Co., Inc., Announce U.S. $50 Million Funding Initiative to Eliminate River Blindness in Africa |
| Dec. 04, 2007 |
|
Merck Anticipates Earnings per Share Growth in 2008; Reaffirms Long-Term, Double-Digit Compound Annual EPS Growth from 2005 to 2010, Excluding Certain Items |
| Nov. 27, 2007 |
|
Merck Announces First-Quarter 2008 Dividend |
| Nov. 26, 2007 |
|
GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR® (lovastatin) from Merck & Co., Inc. |
| Nov. 26, 2007 |
|
Thomas H. Glocer Elected to Merck Board of Directors |
The information contained in each news release posted on this page was factually accurate on the date it was issued. The company assumes no duty to update the information to reflect subsequent developments. Readers of the news releases should not rely upon the information as current or accurate after their issuance dates.
